Similar to DPP4 inhibitors, systemic anti-inflammatory effects have been associated with the use of GLP1 RAs in patients with T2D, as a consequence of the inhibitory activity on cytokine release, due to their interference with NF-kB signaling pathways [58]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.